頁籤選單縮合
題 名 | SGLT-2抑制劑對心血管及腎臟的影響=SGLT-2i, Cardiovascular and Renal Outcomes in Type II Diabetes |
---|---|
作 者 | 楊璦瑜; 劉錦鳳; | 書刊名 | 藥學雜誌 |
卷 期 | 35:4=141 2019.12[民108.12] |
頁 次 | 頁9-13 |
分類號 | 418.271 |
關鍵詞 | SGLT-2抑制劑; 心血管; 腎臟; |
語 文 | 中文(Chinese) |
中文摘要 | 第二型糖尿病的特徵是高血糖、胰島素阻抗、胰島素分泌異常,治療的目標是預 防或延緩併發症並維持生活品質。美國糖尿病與歐洲糖尿病協會於2018 年更新了關 於第二型糖尿病管理的聲明,建議在慢性腎臟疾病、心臟衰竭、動脈粥狀硬化的心 血管疾病病人使用 SGLT-2i (Sodium-glucose co-transporter-2 inhibitor) 是有益的。評估 SGLT-2i 對心血管影響的隨機雙盲臨床試驗:在併有心血管疾病或心血管疾病風險的 第二型糖尿病患者,使用 empagliflozin 及 canagliflozin 與安慰劑相比顯示降低主要不 良心血管事件,而 dapagliflozin 顯示則無差異。文內同時分析觀察性研究結果。再者 糖尿病是引起慢性腎臟疾病的風險因子,本主題將論述 SGLT-2 抑制劑使用於第二型 糖尿病對心血管及腎臟的影響。 |
英文摘要 | Type 2 diabetes mellitus is characterized by hyperglycemia, insulin resistance, and impaired insulin secretion. The goals of treatment for type 2 diabetes are to prevent or delay complications and maintain quality of life. The American Diabetes Association and the European Association for the Study of Diabetes in 2018 update the statements on the management of type 2 diabetes in adults. For patients with chronic kidney disease or heart failure and atherosclerotic cardiovascular disease, an Sodium-glucose co-transporter 2 inhibitor with proven benefit is recommended. In the randomized, double-blind trials evaluated the cardiovascular safety of the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor. In patients with type 2 diabetes who had or were at risk for cardiovascular disease, treatment with empagliflozin and canagliflozin did result in a lower rate of major adverse cardiovascular events than placebo, but dapagliflozin did not significant different. And to evaluate cardiovascular outcome of real-world observational study. Diabetes is one of the risk factors for chronic kidney diseas. This article will review the cardiovascular and renal outcomes of Sodium-glucose co-transporter 2 inhibitors for the treatment of type 2 diabetes mellitus. |
本系統中英文摘要資訊取自各篇刊載內容。